Interventions for basal cell carcinoma of the skin

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 11, 2020, Pages

  Thomson, Jason ^a   Hogan, Sarah ^a   Leonardi Bee, Jo ^b   Williams, Hywel C ^b   Bath Hextall, Fiona J ^b  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AMINOLEVULINIC ACID METHYL ESTER; CALCITRIOL; DICLOFENAC; EPINEPHRINE; FLUOROURACIL; IMIQUIMOD; INGENOL; PROTAMINE; SOLASODINE; TAZAROTENE; VALPROIC ACID; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; METHYL 5-AMINOLEVULINATE; PHOTOSENSITIZING AGENT;

ARTICLE; BASAL CELL CARCINOMA; CANCER RECURRENCE; CRYOSURGERY; DRUG EFFECT; EVIDENCE BASED MEDICINE; EXCISION; GRAFT NECROSIS; HIGH RISK POPULATION; HISTOLOGY; HUMAN; IMMUNOCOMPETENCE; LOW RISK POPULATION; METHODOLOGY; MOHS MICROGRAPHIC SURGERY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PHOTODYNAMIC THERAPY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN CARCINOMA; SYSTEMATIC REVIEW; TELANGIECTASIA; TREATMENT OUTCOME; WOUND INFECTION; ADULT; CRYOTHERAPY; FEMALE; LOW LEVEL LASER THERAPY; MALE; META ANALYSIS; PHOTOCHEMOTHERAPY; PROCEDURES; RADIOTHERAPY; SKIN TUMOR; TUMOR RECURRENCE;

ADULT; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CRYOTHERAPY; FEMALE; HUMANS; IMIQUIMOD; IMMUNOCOMPETENCE; LASER THERAPY; MALE; MOHS SURGERY; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 85096348926     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003412.pub3     Document Type: Article

References (173)

1. 2005-001474-27. A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001474-27/results (first accessed 12 August 2016). x-wiley/crsRef/15384288
2. Abbade L, Gige T, Amaral V, Aquino S, Miot H. Higher recurrence rates of head and neck nodular basal cell carcinoma treated with topical photodynamic therapy (MAL-PDT) compared to surgical excision: a randomized controlled study. Journal of the American Academy of Dermatology 2015;72(5 Suppl 1):AB185. [CENTRAL: CN-01076055] x-wiley/crsRef/3288325
3. Abd El-Naby NM, El-Far NN, Al-Shenawy H A, Elshwadfy SE, Koura AA. Pulsed dye laser in the treatment of basal cell carcinoma: a single session versus two sessions–a randomized controlled trial. Indian Journal of Dermatology, Venereology, and Leprology 2019;85(5):475. x-wiley/crsRef/15384290
4. Alpsoy E, Yikmaz E, Basaran E, Yazar S. Comparison of the effects of intralesional interferon alfa-1a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. Journal of Dermatology 1996;23(6):394-6. [CENTRAL: CN-00127615] x-wiley/crsRef/3288327
5. Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncology 2013;14(7):647-54. [CENTRAL: CN-00872324] x-wiley/crsRef/15384292
6. Jansen MH, Koekelkoren FH, Nelemans PJ, Arits AH, Roozeboom MH, Kelleners-Smeets NW, et al. Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology 2018;79(5):961-4. [CENTRAL: CN-01703594] x-wiley/crsRef/15384293
7. Jansen MH, Mosterd K, Arits AH, Roozeboom MH, Sommer A, Essers BA, et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical Imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Journal of Investigative Dermatology 2018;138(3):527-33. [CENTRAL: CN-01457400] x-wiley/crsRef/15384294
8. Roozeboom MH, Arits AH, Mosterd K, Sommer A, Essers BA, de Rooij MJ, et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. Journal of Investigative Dermatology 2016;136(8):1568-74. [CENTRAL: CN-01197852] x-wiley/crsRef/15384295 [DOI: 10.1016/j.jid.2016.03.043]
9. Avril MF, Auperin A, Margulis A, Gerbaulet A, Duvillard P, Benhamou E, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. British Journal of Cancer 1997;76(1):100-6. [CENTRAL: CN-00141470] x-wiley/crsRef/3288331
10. Petit JY, Avril MF, Margulis A, Chassagne D, Gerbaulet A, Duvillard P, et al. Evaluation of cosmetic results of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plastic and Reconstructive Surgery 2000;105(7):2544-51. [CENTRAL: CN-00278207] x-wiley/crsRef/3288332
11. Basset-Seguin N, Ibbotson S, Emtestam L, Tarstedt M, Morton C, Maroti M, et al. Methyl aminolaevulinate photodynamic therapy vs. cryotherapy in primary superficial basal cell carcinoma: results of a 36-month follow-up. British Journal of Dermatology 2005;153(1):29. x-wiley/crsRef/15384296
12. Basset-Seguin N, Ibbotson S, Emtestam L, Tarstedt M, Morton C, Maroti M, et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatolology 2008;18(5):547-53. [CENTRAL: CN-00668120] x-wiley/crsRef/3288334
13. Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PS, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncology 2014;15(1):96-105. [CENTRAL: CN-00959373] x-wiley/crsRef/15384297
14. Williams HC, Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative Dermatology 2017;137(3):614-9. [CENTRAL: CN-01340067] x-wiley/crsRef/15384298 [EMBASE: 614596349]
15. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens MA. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. Journal of the American Academy of Dermatology 1999;41(6):1002-7. [CENTRAL: CN-00264417] x-wiley/crsRef/3288338
16. Brinkhuizen T, Frencken KJ, Nelemans PJ, Hoff ML, Kelleners-Smeets NW, Zur Hausen A, et al. The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial. Journal of the American Academy of Dermatology 2016;75(1):126-34. [CENTRAL: CN-01342883] x-wiley/crsRef/15384300 [DOI: 10.1016/j.jaad.2016.01.050]
17. Choi SH, Kim KH, Song KH. Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. Journal of the European Academy of Dermatology and Venereology 2015;30(5):783-8. [CENTRAL: CN-01158122] x-wiley/crsRef/15384302 [DOI: 10.1111/jdv.13453]
18. Clover AJ, Salwa S, McKiernan J, Buckley C, Bourke M, Kelly EJ, et al. Prospective randomised control trial comparing electrochemotherapy and surgery for the primary treatment of basal cell carcinoma. Melanoma Research 2016;26:e76. [CENTRAL: CN-01212975] x-wiley/crsRef/15384304 [DOI: 10.1097/CMR.0000000000000285] [EMBASE: 612248066]
19. Clover AJ, Salwa SP, Bourke MG, McKiernan J, Forde PF, O'Sullivan ST, et al. Electrochemotherapy for the treatment of primary basal cell carcinoma; a randomised control trial comparing electrochemotherapy and surgery with five year follow up. European Journal of Surgical Oncology 2020;46(5):847-54. [CENTRAL: CN-02049463] x-wiley/crsRef/15384305 [PMID: 31862134]
20. Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, et al. Intralesional interferon therapy for basal cell carcinoma. Journal of the American Academy of Dermatology 1990;23(4 Pt 1):694-700. [CENTRAL: CN-00071018] x-wiley/crsRef/3288344
21. Edwards L, Tucker SB, Perednia D, Smiles KA, Taylor EL, Tanner DJ, et al. The effects of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinoma. Archives of Dermatology 1990;126(8):1029-32. [CENTRAL: CN-00069443] x-wiley/crsRef/3288346
22. Eigentler TK, Kamin A, Weide BM, Breuninger H, Caroli UM, Möhrle M, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology 2007;57(4):616-21. [CENTRAL: CN-00610509] x-wiley/crsRef/3288348
23. Eimpunth S, Oganesyan G, Hamman MS, Lee RA, Jiang SI, Kim SS. Effectiveness of a 595-nm pulsed dye laser for the treatment of basal cell carcinoma using 1 stacked-pulse session. Journal of the American Academy of Dermatology 2014;70(5 (S1)):AB134. [CENTRAL: CN-01057471] x-wiley/crsRef/3288350
24. Ezughah FI, Dawe RS, Ibbotson SH, Fleming CJ. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment 2008;19(2):111-7. [CENTRAL: CN-00706567] x-wiley/crsRef/3288352
25. Foley P, Freeman M, Menter A, Siller G, El-Azhary RA, Gebauer K, et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology 2009;48(11):1236-45. [CENTRAL: CN-00734005] x-wiley/crsRef/15384307
26. Foley P, Freeman M, Siller G, Gebauer K, Murrell D, Barnetson R, et al. A phase III randomized study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). Journal of the European Academy of Dermatology and Venereology 2003;17(Suppl 3):231. [CENTRAL: CN-00478536] x-wiley/crsRef/15384308
27. Foley P, Freeman M, Menter A, Siller G, El-Azhary RA, Gebauer K, et al. Photodynamic therapy with methyl aminolevulinate from primary nodular basal cell carcinoma:results of two randomized studies. International Journal of Dermatology 2009;48(11):1236-45. [CENTRAL: CN-00734005] x-wiley/crsRef/15384310
28. Tope WD, Menter A, El Azhary R, Soto P. A comparison of topical MAL-PDT versus placebo-PDT in nodular basal cell carcinoma: results of a North American study. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology; 2005 Sep 28-Oct 03; Kuala Lumpur, Malaysia. 2005:376. [CENTRAL: CN-00602617] x-wiley/crsRef/15384311
29. Garcia-Martin E, Gil-Arribas LM, Idoipe M, Alfaro J, Pueyo V, Pablo LE, et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. British Journal of Ophthalmology 2011;95(10):1393-6. [CENTRAL: CN-00801928] x-wiley/crsRef/15384313
30. Geisse JK, Marks R, Owens ML, Andres K, Ginkel AM. Imiquimod 5% cream for 12 weeks treating superficial BCC. In: The 8th World Congress on Cancer of the Skin; 2001 July 18-21; Zurich, Switzerland. 2001:P58. [CENTRAL: CN-00520431] x-wiley/crsRef/3288356
31. Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a randomized, vehicle-controlled study. Journal of the American Academy of Dermatology 2002;47(3):390-8. [CENTRAL: CN-00390933] x-wiley/crsRef/3288357
32. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology 2004;50(5):722-33. [CENTRAL: CN-00469536] x-wiley/crsRef/3288359
33. Haak CS, Togsverd-Bo K, Thaysen-Petersen D, Wulf HC, Paasch U, Anderson RR, et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas - a randomized clinical trial. British Journal of Dermatology 2015;172(1):215-22. [CENTRAL: CN-01039978] x-wiley/crsRef/3288361
34. Hall VL, Leppard BJ, McGill J, Kesseler ME, White JE, Goodwin P. Treatment of basal cell carcinoma: comparison of radiotherapy and cryotherapy. Clinical Radiology 1986;37(1):33-4. [CENTRAL: CN-00478536] x-wiley/crsRef/3288363
35. Karsai S, Friedl H, Buhck H, Jünger M, Podda M. The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: Outcome of a double-blind randomized placebo-controlled trial. British Journal of Dermatology 2015;172(3):677-83. [CENTRAL: CN-01068975] x-wiley/crsRef/3288365
36. Kessels J, Voeten L, Nelemans P, Cleutjens J, Hillen LM, Mosterd K, et al. Topical sinecatechins, 10%, ointment for superficial basal cell carcinoma: A randomized clinical trial. JAMA Dermatology 2017;153(10):1061-3. [CENTRAL: CN-01420948] x-wiley/crsRef/15384315
37. Kessels JP, Kreukels H, Nelemans PJ, Roozeboom MH, van Pelt H, Mosterd K, et al. Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolaevulinic acid 20% vs. two-stage topical methyl aminolaevulinate: results of a randomized controlled trial. British Journal of Dermatology 2018;178(5):1056-63. [CENTRAL: CN-01991773] x-wiley/crsRef/15384317
38. Kuijpers DI, Thissen MR, Thissen CA, Neumann MH. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. Journal of Drugs in Dermatology 2006;5(7):642-5. [CENTRAL: CN-00566805] x-wiley/crsRef/3288448
39. Kuijpers DI, Thissen MR, Berretty PJ, Ideler FH, Nelemans PJ, Neumann MH. Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatologic Surgery 2007;33(5):579-87. [CENTRAL: CN-00588176] x-wiley/crsRef/3288367
40. Thissen MR, Nieman FH, Ideler AH, Berretty PJ, Neumann HA. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatologic Surgery 2000;26(8):759-64. [CENTRAL: CN-00298974] x-wiley/crsRef/15384318
41. Landthaler M, Braun-Falco O. Use of the TDF factor in soft roentgen radiotherapy [Anwendung des TDF-Faktors in der Röntgenweichstrahlentherapie]. Hautarzt 1989;40(12):774-7. [CENTRAL: CN-00194309] x-wiley/crsRef/15384320 [PMID: 2695500]
42. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicentre 6-week dose-response trial. Journal of the American Academy of Dermatology 2001;44(5):807-13. [CENTRAL: CN-00326531] x-wiley/crsRef/3288373
43. Miller BH, Shavin JS, Cognetta A, Taylor RJ, Salasche S, Korey A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. Journal of the American Academy of Dermatology 1997;36(1):72-7. [CENTRAL: CN-00135753] x-wiley/crsRef/3288375
44. Morton CA, Dominicus R, Radny P, Dirschka T, Hauschild A, Reinhold U, et al. A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). British Journal of Dermatology 2018;179(2):309-19. [CENTRAL: CN-02000788] x-wiley/crsRef/15384322 [PMID: 29432644]
45. Mosterd K, Thissen MR, Nelemans P, Kelleners-Smeets NW, Janssen RL, Broekhof KG, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. British Journal of Dermatology 2008;159(4):864-70. [CENTRAL: CN-00667266] x-wiley/crsRef/15384323
46. Roozeboom MH, Aardoom MA, Nelemans PJ, Thissen MR, Kelleners-Smeets NW, Kuijpers DI, et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology August 2013;69(2):280-7. [CENTRAL: CN-00876800] x-wiley/crsRef/15384324 [DOI: 10.1016/j.jid.2016.03.043]
47. Punjabi S, Cook LJ, Kersey P, Marks R, Cerio R. Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicentre study. International Journal of Dermatology 2008;47(1):78-82. [CENTRAL: CN-00629144] x-wiley/crsRef/15384325
48. Punjabi S, Cook LJ, Kersey P, Marks R, Finlay A, Sharp G, et al. A double-blind, multicentre parallel group study of BEC-5 cream in basal cell carcinoma. European Academy of Dermatology & Venereology 2000;14(Suppl 1):49. [CENTRAL: CN-01616931] x-wiley/crsRef/15384326
49. Rhodes LE, de Rie M, Enström Y, Groves R, Morken T, Goulden V, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma. Archives of Dermatology 2004;140(1):17-23. [CENTRAL: CN-00460094] x-wiley/crsRef/3288383
50. Rhodes LE, de Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, et al. Five year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of Dermatology 2007;143(9):1131-6. [CENTRAL: CN-00612111] x-wiley/crsRef/15384327
51. Rogozinski TT, Jablonska S, Brzoska IM, Wohr C, Gaus W. Intralesional treatment with recombinant interferon beta is an effective alternative for the treatment of basal cell carcinoma. Double-blind, placebo-controlled study. [Doogniskowe podawanie rekombinantowego interferonu beta. Skuteczna alternatywa w leczeniu basalimoma (wyniki podwojnie slepej proby)]. Przeglad Dermatologiczny 1997;84(3):259-63. [CENTRAL: CN-00193051] x-wiley/crsRef/3288387
52. Romagosa R, Saap L, Givens M, Salvarrey A, He JL, Hsia SL, et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatologic Surgery 2000;26(4):338-40. [CENTRAL: CN-00296475] x-wiley/crsRef/3288389
53. Salmanpoor R, Motevalli D, Saki N, Saki M. Efficacy of excisional surgery, curettage and combined curettage and electrodessication in treatment of basal cell carcinoma. Iranian Journal of Dermatology 2012;15(2):66-7. [CENTRAL: CN-00908884] x-wiley/crsRef/3288393
54. Salmivuori MK, Grönroos M, Tani T, Pölönen I, Räsänen J, Annala L, et al. Hexylaminolevulinate and aminolevulinic acid nanoemulsion have similar tolerability, initial efficacy and cosmetic outcome as methylaminolevulinate in photodynamic therapy of basal cell carcinoma in a prospective randomized double-blinded trial. Journal of Investigative Dermatology 2019;139(9):S234. [CENTRAL: CN-01978390] x-wiley/crsRef/15384329 [DOI: 10.1016/j.jid.2019.07.119]
55. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Diez G, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. British Journal of Dermatology 2005;152(5):939-47. [CENTRAL: CN-00513173] x-wiley/crsRef/3288397
56. Shumack S, Marks R, Amies M, Andres K, Ginkel AM. Imiquimod 5% cream for 6 weeks treating nodular BCC. 8th World Congress on Cancers of the Skin, Zurich, Switzerland 2001;-:p55. [CENTRAL: CN-00849091] x-wiley/crsRef/3288399
57. Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology 2002;138(9):1165-71. [CENTRAL: CN-00398024] x-wiley/crsRef/3288400
58. Robinson JK, Marks R, Owens ML, Andres K, Ginkel AM. Imiquimod 5% cream for 12 weeks treating nodular BCC. 8th World Congress on Cancer of the Skin, Zurich, Switzerland 2001;-(-):p57. [CENTRAL: CN-00849091] x-wiley/crsRef/3288402
59. Schumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter, A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Archives of Dermatology 2002;138(9):1165-71. [CENTRAL: CN-00398024] x-wiley/crsRef/3288403
60. Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (Ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomised phase IIa trial. Australasian Journal of Dermatology 2010;51(2):99-105. [CENTRAL: CN-00771587] x-wiley/crsRef/3288405
61. Essers BA, Dirksen CD, Nieman FH, Smeets NW, Krekels GA, Prins MH, et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Archives of Dermatology 2006;142(2):187-94. [CENTRAL: CN-00555278] x-wiley/crsRef/15384330
62. Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncology 2008;9(12):1149-56. [CENTRAL: CN-00665334] x-wiley/crsRef/15384331
63. Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, Nieman FH, et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004;364(9447):1766-72. [CENTRAL: CN-00492695] x-wiley/crsRef/3288407
64. Van Loo E, Mosterd K, Krekels GA, Roozeboom MH, Ostertag JU, Dirksen CD, et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European Journal of Cancer 2014;50(17):3011-20. [CENTRAL: CN-01043314] x-wiley/crsRef/15384332
65. Soler AM, Angell-Petersen E, Warloe T, Tausjo J, Steen HB, Moan J, et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: A comparison of two light sources. Photochemistry and Photobiology 2000;71(6):724-9. [CENTRAL: CN-00297518] x-wiley/crsRef/3288409
66. Rosen R, Freeman M, Zibert JR, Katsamas J, Knudsen KM, Spelman L. Ingenol mebutate 0.05% gel under occlusion is efficacious in treating superficial basal cell carcinoma. British Journal of Dermatology 2014;171(Suppl 4):50. [CENTRAL: CN-01057057] x-wiley/crsRef/3288411
67. Sterry W, Bichel J, Andres K, Ginkel AM. Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. In: 8th World Congress on cancers of the skin, Zurich, Switzerland. 2001:61. [CENTRAL: CN-00478768] x-wiley/crsRef/15384334
68. Sterry W, Bichel J, Ding L, Ginkel AM. Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. x-wiley/crsRef/15384335
69. Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology 2002;147(6):1227-36. [CENTRAL: CN-00411766] x-wiley/crsRef/15384336 [PMID: 12452875]
70. Sterry W, Bichel J, Andres K, Ginkel AM. Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. 8th World Congress on cancers of the skin, Zurich, Switzerland 2001;-(-):p61. [CENTRAL: CN-00478768] x-wiley/crsRef/15384338
71. Sterry W, Bichel J, Ding L, Ginkel AM. Imiquimod 5% cream for 6 weeks with occlusion treating nodular BCC. In: 8th World Congress on Cancer of the skin, Zurich, Switzerland. 2001. x-wiley/crsRef/15384339
72. Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology 2002;147(6):1227-36. [CENTRAL: CN-00411766] x-wiley/crsRef/15384340
73. Szeimies RM, Ibbotson S, Murrell DF, Rubel D, Frambach Y, De Berker D, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology 2008;22(11):1302-11. [CENTRAL: CN-00668334] x-wiley/crsRef/3288419
74. Tran HT, Lee RA, Oganesyan G, Jiang SB. Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers in Surgery and Medicine 2012;44(6):459-67. [CENTRAL: CN-00969795] x-wiley/crsRef/15384342
75. Wang I, Bendsoe N, Klinteberg CA, Enejder AM, Andersson-Engels S, Svanberg S, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. British Journal of Dermatology 2000;144(4):832-40. [CENTRAL: CN-00326537] x-wiley/crsRef/3288426
76. Al-Niaimi F, Sheth N, Kurwa HA, Mallipeddi R. Photodynamic therapy followed by Mohs micrographic surgery compared to mohs micrographic surgery alone for the treatment of basal cell carcinoma: results of a pilot single-blinded randomised controlled trial. Journal of Cutaneous and Aesthetic Surgery 2015;8(2):88-91. [CENTRAL: CN-02012011] x-wiley/crsRef/3288428
77. Arits AH, Spoorenberg E, Mosterd K, Nelemans P, Kelleners-Smeets NW, Essers BA. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma. British Journal of Dermatology 2014;171(6):1501-07. [CENTRAL: CN-01117058] x-wiley/crsRef/3288430
78. Berroeta L, Clark C, Dawe RS, Ibbotson SH, Fleming CJ. A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. British Journal of Dermatology 2007;157(2):401-3. [CENTRAL: CN-00610206] x-wiley/crsRef/3288432
79. Butler DF, Parekh PK, Lenis A. Imiquimod 5% cream as adjunctive therapy for primary solitary, nodular basal cell carcinomas before Mohs Micrographic Surgery: a randomized, double blind vehicle-controlled study. Dermatologic Surgery 2009;35(1):24-9. [CENTRAL: CN-00669203] x-wiley/crsRef/3288436
80. Čarija A, Puizina-Ivić N, Vuković D, Mirić Kovačević L, Čapkun V. Single treatment of low-risk basal cell carcinomas with pulsed dye laser-mediated photodynamic therapy (PDL-PDT) compared with photodynamic therapy (PDT): a controlled, investigator-blinded, intra-individual prospective study. Photodiagnosis and Photodynamic Therapy 2016;16:60-5. [CENTRAL: CN-01342603] x-wiley/crsRef/15384344
81. Cho EA, Moloney FJ, Cai H, Au-Yeung A, China C, Scolyer RA. Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). Lancet 2013;381(9880):1835-43. x-wiley/crsRef/15384346
82. de Haas ER, Kruijt B, Sterenborg HJ, Neumann HM, Robinson DJ. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. Journal of Investigative Dermatology 2006;126(12):2679-86. [CENTRAL: CN-00571166] x-wiley/crsRef/15384348
83. Dessinioti C, Plaka M, Stratigos AJ. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial. Future Oncology 2014;10(6):927-36. x-wiley/crsRef/15384350
84. EduraCT 2013-000092-33. Enhanced efficacy of photodynamic therapy in combination with 5% imiquimod -a randomised, prospective, observer-blinded study in patients with non melanoma skin cancer. www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000092-33 (first received 19 September 2013). x-wiley/crsRef/15384352 [2013-000092-33]
85. 2 laser mode. Journal of the European Academy of Dermatology and Venereology: JEADV 2018;32(11):1897-905. x-wiley/crsRef/15384354 [PMID: 29633367]
86. Groselj A, Bosnjak M, Strojan P, Krzan M, Cemazar M, Sersa G. Efficiency of electrochemotherapy with reduced bleomycin dose in the treatment of nonmelanoma head and neck skin cancer: Preliminary results. Head & Neck 2018;40(1):120-5. [CENTRAL: CN-01475261] x-wiley/crsRef/15384356
87. Huang CC, Boyce S, Northington M, Desmond R, Soong S-J. Randomised, controlled surgical trial of preoperative tumour curettage of basal cell carcinoma in Mohs micrographic surgery. Journal of the American Academy of Dermatology 2004;51(4):585-91. [CENTRAL: CN-00497417] x-wiley/crsRef/3288446
88. Ibbotson S, Dawe R, Moseley H, Samuel I, Ferguson J. A randomized, controlled trial of portable compared with conventional photodynamic therapy for superficial nonmelanoma skin cancer. British Journal of Dermatology 2018;179(Suppl 1):100. [CENTRAL: CN-01620045] x-wiley/crsRef/15384358
89. Lippert J, Šmucler R, Vlk M. Fractional carbon dioxide laser improves nodular basal cell carcinoma treatment with photodynamic therapy with methyl 5-aminolevulinate. Dermatologic Surgery 2013;39(8):1202-8. [CENTRAL: CN-02012012] x-wiley/crsRef/3288452 [PMID: 23725586]
90. Lu W, Feng W, Tang Y, Tao X, Pan L. Study of ALA and small dosage of HPD photodynamic therapy (HPD-PDT) in treatment of skin cancer. Biomedical Research (India) 2017;28(14):6476-9. [CENTRAL: CN-01417427] x-wiley/crsRef/15384360
91. Lui H, Hobbs L, Tope WD, Lee PK, Elmets C, Provost N, et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes. Archives of Dermatology 2004;140(1):26-32. [CENTRAL: CN-00460095] x-wiley/crsRef/3288371
92. Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncology 2015;16(6):716-28. [CENTRAL: CN-01109355] x-wiley/crsRef/15384362
93. NCT01033019. To evaluate the safety, local tolerability, PK and PD of LDE225 on sporadic superficial and nodular skin basal cell carcinomas (sBCC). clinicaltrials.gov/ct2/show/NCT01033019 (first received 16 December 2009). x-wiley/crsRef/15384364
94. Nguyen KP, Knuiman GJ, Blokx WA, Hoogedoorn L, Smits T, Gerritsen MJ. Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial. Journal of Dermatological Treatment 2019;30(2):194-9. [CENTRAL: CN-01930357] x-wiley/crsRef/15384366 [DOI: 10.1080/09546634.2018.1484558]
95. Quirk C, Gebauer K, De'Ambrosis B, Slade HB, Meng TC. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis 2010;85(6):318-24. x-wiley/crsRef/3288458 [PMID: 20666194]
96. Radiotis G, Roberts N, Czajkowska Z, Khanna M, Korner A. Nonmelanoma skin cancer: disease-specific quality-of-life concerns and distress. Oncology Nursing Forum 2014;41(1):57-65. x-wiley/crsRef/3288460 [PMID: 24368239]
97. Schleier P, Berndt A, Kolossa S, Zenk W, Hyckel P, Schultze-Mosgau S. Comparison of aminolevulinic acid (ALA)-thermogel-PSDT with methyl-ALA-thermogel-PDT in basal cell carcinoma. Photodiagnosis and Photodynamic Therapy 2007;4(3):197-201. [CENTRAL: CN-01951238] x-wiley/crsRef/3288395
98. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. New England Journal of Medicine 2012;366(23):2171-9. x-wiley/crsRef/3288462 [PMID: 22670903]
99. Spencer JM. Pilot study of Imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular and basal cell carcinoma. Dermatologic Surgery 2006;32(1):63-9. [CENTRAL: CN-00554023] x-wiley/crsRef/15384368 [PMID: 16393600]
100. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. New England Journal of Medicine 2012;366(23):2180-8. [CENTRAL: CN-00814383] x-wiley/crsRef/3288464
101. Van der Geer S, Martens J, Van Roij J, Brand E, Ostertag JU, Verhaegh ME, et al. Imiquimod 5% cream as pre-treatment of Mohs Micrographic Surgery for nodular basal cell carcinoma in the face, a prospective randomized controlled study. British Journal of Dermatology 2012;167(1):110-5. [CENTRAL: CN-00856436] x-wiley/crsRef/3288468
102. Vijlder HC, Sterenborg HJ, Neumann HA, Robinson DJ, Haas ER. Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta Dermato-Venereologica 2012;92(6):641-7. [CENTRAL: CN-00878966] x-wiley/crsRef/3288470
103. Wettstein R, Erba P, Itin P, Schaefer DJ, Kalbermatten DF. Treatment of basal cell carcinoma with surgical excision and perilesional interferon-alpha. Journal of Plastic, Reconstructive and Aesthetic Surgery 2013;66(7):912-6. [CENTRAL: CN-00964441] x-wiley/crsRef/3288472
104. Zane C, Facchinetti E, Arisi M, Ortel B, Calzavara-Pinton P. Pulsed CO2 laser ablation of superficial basal cell of limbs and trunk: a comparative randomized clinical trial with cryotherapy and surgical ablation. Dermatologic Surgery 2017;43(7):920-7. [CENTRAL: CN-01401171] x-wiley/crsRef/15384370
105. Bunker C. 5 Fluoracil/Adrenaline injectable gel in basal cell carcinoma. National Research Register. x-wiley/crsRef/3288434
106. IRCT2017030732933N1. A comparison between efficacy and safety of 585-nanometer pulsed dye laser alone and with cryotherapy in treating superficial basal cell carcinoma. en.irct.ir/trial/25544 (first received 21 May 2017). x-wiley/crsRef/15384372
107. ISRCTN 92678315. Effect of penetration enhancers in topical photodynamic therapy [Comparison of 20% Aminolaevulinic acid (ALA) versus 20% ALA 2% dimethyl sulphoxide (DMSO) 2% ethylene diamine tetraacetic acid (EDTA) in topical photodynamic therapy]. doi.org/10.1186/ISRCTN92678315 (first received 8 April 2002). x-wiley/crsRef/15384374
108. Kang K, Han M, Cong M, Chen S, Zhang X, Zhang J. The effects of Ella light power combined with imiquimod cream on basal cell carcinoma. Anti-Tumor Pharmacy 2018;8(2):258-62. x-wiley/crsRef/15384376 [en.cnki.com.cn/Article_en/CJFDTotal-LIYX201802033.htm]
109. Ma X, Li L, Ma X, Yang J, He Y. Effect of adriamycin combined with cisplatin on basal cell carcinoma and the level of vascular endothelial growth factor in patients. Anti-tumor Pharmacy 2018;6:951-4. x-wiley/crsRef/15384378
110. RPCEC00000147. Efficacy study, randomized, controlled, with CIGB-128-A injected perilesional in basal cell carcinoma in different treatment schedules (InCarbacel-V study). registroclinico.sld.cu/en/trials/RPCEC00000147-En (first received 1 February 2013). x-wiley/crsRef/15384380
111. EudraCT 2016-002255-25. Electrochemotherapy compared with radiotherapy for the treatment of basal cell carcinoma. www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002255-25 (first received 12 September 2016). x-wiley/crsRef/15384382 [2016-002255-25]
112. NCT02242929. Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma (SCIN). clinicaltrials.gov/ct2/show/NCT02242929 (first received 17 September 2014). x-wiley/crsRef/15384384
113. NCT03573401. A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). clinicaltrials.gov/ct2/show/NCT03573401 (first received 29 June 2018). x-wiley/crsRef/15384386
114. Breuninger H, Dietz K. Prediction of subclinical tumor infiltration in basal cell carcinoma. Journal of Dermatologic Surgery and Oncology 1991;17(7):574-8.
115. Campana LG, Marconato R, Valpione S, Galuppo S, Alaibac M, Rossi CR, et al. Basal cell carcinoma: 10-year experience with electrochemotherapy. Journal of Translational Medicine 2017;15(1):122.
116. Chiller K, Passaro D, McCalmont T, Vin-Christian K. Efficacy of curettage before excision in clearing surgical margins of nonmelanoma skin cancer. Archives of Dermatology 2000;136(11):1327-32.
117. Collier NJ, Haylett AK, Wong TH, Morton CA, Ibbotson SH, McKenna KE, et al. Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta-analysis. British Journal of Dermatology 2018;179(6):1277-96.
118. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Modern Pathology 2006;19(S2):S127.
119. Dessinioti C, Antoniou C, Katsambas A, Stratigos AJ. Basal cell carcinoma: what’s new under the sun. Photochemistry and Photobiology 2010;86(3):481-91.
120. Drucker AM, Adam GP, Rofeberg V, Gazula A, Smith B, Moustafa F, et al. Treatments of primary basal cell carcinoma of the skin: a systematic review and network meta-analysis. Annals of Internal Medicine 2018;169(7):456-66.
121. Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G. Imiquimod in basal cell carcinoma: how does it work? British Journal of Dermatology 2003;149:57-8.
122. Fergusson D, Aaron SD, Guyatt G, Hébert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ 2002;325(7365):652-4.
123. Franchimont C, Pierard GE, Cauwenberge D, Andc MD, Lapiere H. Episodic progression and regression of basal cell carcinomas. British Journal of Dermatology 1982;106(3):305-10.
124. Fritsch C, Goerz G, Ruzicka T. Photodynamic therapy in dermatology. Archives of Dermatology 1998;134(2):207-14.
125. McMaster University (developed by Evidence Prime, Inc.) GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.), accessed 2018. Available at gradepro.org.
126. Griffiths RW, Suvarna SK, Stone J. Do basal cell carcinomas recur after complete conventional surgical excision? British Journal of Plastic Surgery 2005;58(6):795-805.
127. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona. Journal of the American Academy of Dermatology 2001;45(4):528–36.
128. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.
129. Hruza GJ. Mohs micrographic surgery local recurrences. Journal of Dermatologic Surgery and Oncology 1994;20(9):573-7.
130. Ibbotson S, McKenna K. Principles of photodynamic therapy. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley & Sons, Ltd, 2016.
131. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996;272(5268):1668-71.
132. Jung DS, Cho HH, Ko HC, Bae YC, Oh CK, Kim MB, et al. Recurrent basal cell carcinoma following ablative laser procedures. Journal of the American Academy of Dermatology 2011;64(4):723-9.
133. Karagas MR, Greenberg ER, Spencer SK, Stukel TA, Mott LA. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. International Journal of Cancer 1999;81(4):555–9.
134. Kelleners-Smeets NW, Mosterd K, Nelemans PJ. Treatment of low-risk basal cell carcinoma. Journal of Investigative Dermatology 2017;137(3):539-40.
135. Kimyai-Asadi A, Alam M, Goldberg LH, Peterson SR, Silapunt S, Jih MH. Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. Journal of the American Academy of Dermatology 2005;53(3):464-8.
136. Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatric Radiology 2009;39(1):27-31.
137. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. British Journal of Dermatology 2012;166(5):1069-80.
138. Madan V, Lear JT. Basal cell carcinoma. In: Rook's Textbook of Dermatology, Ninth Edition. John Wiley & Sons, Ltd, 2016.
139. Mallon E, Dawber R. Cryosurgery in the treatment of basal cell carcinoma: assessment of one and two freeze-thaw cycle schedules. Dermatologic Surgery 1996;22(10):854-8.
140. Miller SJ. Biology of basal cell carcinoma (part 1). Journal of the American Academy of Dermatology 1991;24(1):1-13.
141. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine 2009;6(7):e1000097. [PMID: 19621072]
142. Mosterd K, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Aesthetic evaluation after non-invasive treatment for superficial basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology: JEADV 2013;27(5):647-50. [DOI: 10.1111/j.1468-3083.2011.04347.x]
143. Mulholland MW, Lillemoe KD, Doherty GM, Maier RV, Simeone DM, Upchurch GR. Greenfield's surgery: Scientific principles & practice. Lippincott Williams & Wilkins, 2012.
144. Muller FM, Dawe RS, Moseley H, Fleming CJ. Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. Dermatologic Surgery 2009;35(9):1349-54.
145. National Cancer Intelligence Network (NCIN). Data Briefing. The importance of skin cancer registration; September 2010. Available at www.ncin.org.uk/publications/data_briefings/skin_cancer_registration.
146. Nizamoglu M, Douglas H, McArdle C, Mathew B, Vize C, Matteucci P. Using frozen section margin control technique to manage non-melanomatous skin lesions in high-risk sites. Journal of Plastic, Reconstructive & Aesthetic Surgery 2016;69(5):657-62.
147. Page MJ, Higgins JP, Sterne JA. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
148. Raasch BA, Buettner PG. Multiple nonmelanoma skin cancer in an exposed Australian population. International Journal of Dermatology 2002;41(10):652-8.
149. Randle HW. Basal cell carcinoma identification and treatment of the high-risk patient. Dermatologic Surgery 1996;22(3):255-61.
150. The Cochrane Collaboration Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, May 2020. available at https://training.cochrane.org/.
151. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, Kerl H. Epidemiology and aetiology of basal cell carcinoma. British Journal of Dermatology 2007;157(s2):47-51.
152. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. Journal of the American Academy of Dermatology 2012;66(3):486-93.
153. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. Journal of Dermatologic Surgery and Oncology 1989;15(3):315-28.
154. Schlessinger DI, Iyengar S, Yanes AF, Lazaroff JM, Godinez-Puig V, Chen BR, et al. Development of a core outcome set for clinical trials in basal cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials 2017;18(1):490.
155. Schulz KF, Chalmers I, Hayes RJ. Empirical evidence of bias. JAMA 1995;273:408-12.
156. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Medicine 2010;8(1):18.
157. Schünemann H, Brozek J, Oxman A editors. GRADE handbook. The GRADE Working Group, 2013.
158. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. British Journal of Dermatology 2002;147(1):41-7.
159. Shah SM, Konnikov N, Duncan LM, Tannous ZS. The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas. Lasers in Surgery and Medicine 2009;41(6):417-22.
160. Singh T, Katiyar SK. Green tea polyphenol,(−)-epigallocatechin-3-gallate, induces toxicity in human skin cancer cells by targeting β-catenin signaling. Toxicology and Applied Pharmacology 2013;273(2):418-24.
161. Sloan KB, Sherertz EF, McTiernan RG. The effect of 5-fluorouracil on inhibition of epidermal DNA synthesis in vivo: a comparison of the effect of formulations and a prodrug of 5-FU. Archives of Dermatological Research 1990;282(7):484-6.
162. Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. British Journal of Dermatology 2008, 2008;159(1):35-48.
163. Ting PT, Kasper R, Arlette JP. Metastatic basal cell carcinoma: report of two cases and literature review. Journal of Cutaneous Medicine and Surgery 2005;9(1):10-5.
164. Tucker SB, Polasek JW, Perri AJ, Goldsmith EA. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. Journal of the American Academy of Dermatology 2006;54(6):1033-8.
165. van Delft Lc, Nelemans PJ, Jansen MH, Arits H, Roozeboom MH, Hamid MA, et al. Histologic subtype of treatment failures after noninvasive therapy for superficial basal cell carcinoma: An observational study. Journal of the American Academy of Dermatology 2019, 2019;80(4):1022-8. [DOI: 10.1016/j.jaad.2018.12.028]
166. van der Most RG, Himbeck R, Aarons S, Carter SJ, Larma I, Robinson C, et al. Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotides. Journal of Immunotherapy 2006;29(2):134-42.
167. Venables ZC, Nijsten TA, Wong KF, Autier P, Broggio J, Deas A, et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the United Kingdom 2013-2015: a cohort study. British Journal of Dermatology 2019 Mar 12 [Epub ahead of print]. [DOI: 10.1111/bjd.17873]
168. Verkouteren JA, Ramdas KH, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: scholarly review. British Journal of Dermatology 2017;177(2):359–72.
169. Wang H, Xu Y, Shi J, Gao X, Geng L. Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. Photodermatology, Photoimmunology & Photomedicine 2015;31(1):44-53.
170. Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Archives of Dermatology 1987;123(3):340-4.
171. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003;327(7418):794-8.
172. Bath-Hextall F, Bong J, Perkins W, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No: CD003412. [DOI: 10.1002/14651858.CD003412]
173. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No: CD003412. [DOI: 10.1002/14651858.CD003412.pub2]